ID   HuH-28
AC   CVCL_2955
SY   HUH-28; HuH28; HUH28
DR   CLO; CLO_0050855
DR   ArrayExpress; E-MTAB-783
DR   BioSample; SAMN03470952
DR   BioSample; SAMN03472037
DR   BioSample; SAMN10987843
DR   cancercelllines; CVCL_2955
DR   Cell_Model_Passport; SIDM01735
DR   ChEMBL-Cells; CHEMBL3308110
DR   Cosmic; 924163
DR   Cosmic; 1373551
DR   Cosmic; 2674045
DR   DepMap; ACH-000808
DR   GEO; GSM887147
DR   GEO; GSM888219
DR   IARC_TP53; 28291
DR   JCRB; JCRB0426
DR   PharmacoDB; HuH28_638_2019
DR   Progenetix; CVCL_2955
DR   RCB; RCB1943
DR   TKG; TKG 0438
DR   Wikidata; Q54896845
RX   CelloPub=CLPUB00275;
RX   PubMed=2852388;
RX   PubMed=2856443;
RX   PubMed=9290701;
RX   PubMed=20164919;
RX   PubMed=21451941;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26956050;
RX   PubMed=27231123;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31077409;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~80 hours (PubMed=2852388); ~1 week (Note=Lot 09082006), ~88 hours (Note=Lot 01062011), 55-128 hours (Note=Lot 07222016), 5 days (Note=Lot 10022018) (JCRB=JCRB0426).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=3.05%; Native American=0%; East Asian, North=84.08%; East Asian, South=11.01%; South Asian=0%; European, North=0%; European, South=1.86% (PubMed=30894373).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): JCRB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 9,12
ST   D16S539: 9
ST   D18S51: 15
ST   D19S433: 13,14.2
ST   D21S11: 30,33.2
ST   D2S1338: 19
ST   D3S1358: 15,16
ST   D5S818: 9,12
ST   D7S820: 10 (RCB)
ST   D7S820: 10,11 (JCRB; PubMed=25877200; TKG)
ST   D8S1179: 11
ST   FGA: 23
ST   Penta D: 9,10
ST   Penta E: 13,22
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=2852388; DOI=10.1007/BF01851205;
RA   Kusaka Y., Tokiwa T., Sato J.;
RT   "Establishment and characterization of a cell line from a human
RT   cholangiocellular carcinoma.";
RL   Res. Exp. Med. (Berl.) 188:367-375(1988).
//
RX   PubMed=2856443;
RA   Kusaka Y., Muraoka A., Tokiwa T., Sato J.;
RT   "Establishment and characterization of a human cholangiocellular
RT   carcinoma cell line.";
RL   Hum. Cell 1:92-94(1988).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21451941; DOI=10.1007/s00534-011-0376-7;
RA   Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y.,
RA   Tsuchiya T., Gotoh M.;
RT   "Gene expression analysis for predicting gemcitabine resistance in
RT   human cholangiocarcinoma.";
RL   J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26956050; DOI=10.18632/oncotarget.7914;
RA   Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J.,
RA   Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A.,
RA   Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.;
RT   "Antitumor effect of the novel sphingosine kinase 2 inhibitor
RT   ABC294640 is enhanced by inhibition of autophagy and by sorafenib in
RT   human cholangiocarcinoma cells.";
RL   Oncotarget 7:20080-20092(2016).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   El-Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31077409; DOI=10.1002/hep.30704;
RA   Sittithumcharee G., Suppramote O., Vaeteewoottacharn K.,
RA   Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M.,
RA   Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K.,
RA   Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P.,
RA   Pairojkul C., Wongkham S., Sampattavanich S., Okada S.,
RA   Jirawatnotai S.;
RT   "Dependency of cholangiocarcinoma on cyclin D-dependent kinase
RT   activity.";
RL   Hepatology 70:1614-1630(2019).
//